FI3625213T3 - (+)-3-(2,3-Difluorifenyyli)-3-metoksipyrrolidiini-fumaraatti, menetelmä sen valmistamiseksi ja sen käytöt - Google Patents
(+)-3-(2,3-Difluorifenyyli)-3-metoksipyrrolidiini-fumaraatti, menetelmä sen valmistamiseksi ja sen käytöt Download PDFInfo
- Publication number
- FI3625213T3 FI3625213T3 FIEP18730980.2T FI18730980T FI3625213T3 FI 3625213 T3 FI3625213 T3 FI 3625213T3 FI 18730980 T FI18730980 T FI 18730980T FI 3625213 T3 FI3625213 T3 FI 3625213T3
- Authority
- FI
- Finland
- Prior art keywords
- formula
- salt
- disorder
- formula iib
- disease
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 4
- 238000002360 preparation method Methods 0.000 title claims 2
- FHXIIHXNSWGBPV-WLHGVMLRSA-N C(\C=C\C(=O)O)(=O)O.FC1=C(C=CC=C1F)C1(CNCC1)OC Chemical compound C(\C=C\C(=O)O)(=O)O.FC1=C(C=CC=C1F)C1(CNCC1)OC FHXIIHXNSWGBPV-WLHGVMLRSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 206010012289 Dementia Diseases 0.000 claims 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 208000028017 Psychotic disease Diseases 0.000 claims 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000000642 iatrogenic effect Effects 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 230000003542 behavioural effect Effects 0.000 claims 2
- 239000001530 fumaric acid Substances 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 claims 1
- 206010000117 Abnormal behaviour Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020852 Hypertonia Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010028347 Muscle twitching Diseases 0.000 claims 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000020186 Schizophreniform disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 239000013256 coordination polymer Substances 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002545 drug psychosis Diseases 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17171938 | 2017-05-19 | ||
| EP17195451 | 2017-10-09 | ||
| EP17207406 | 2017-12-14 | ||
| EP18151428 | 2018-01-12 | ||
| PCT/EP2018/063123 WO2018211080A1 (en) | 2017-05-19 | 2018-05-18 | (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3625213T3 true FI3625213T3 (fi) | 2023-05-29 |
Family
ID=62599537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18730980.2T FI3625213T3 (fi) | 2017-05-19 | 2018-05-18 | (+)-3-(2,3-Difluorifenyyli)-3-metoksipyrrolidiini-fumaraatti, menetelmä sen valmistamiseksi ja sen käytöt |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11078158B2 (enExample) |
| EP (1) | EP3625213B1 (enExample) |
| JP (1) | JP7126522B2 (enExample) |
| CN (1) | CN110621659B (enExample) |
| CA (1) | CA3064136A1 (enExample) |
| DK (1) | DK3625213T3 (enExample) |
| ES (1) | ES2943252T3 (enExample) |
| FI (1) | FI3625213T3 (enExample) |
| PL (1) | PL3625213T3 (enExample) |
| WO (1) | WO2018211080A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020239568A1 (en) * | 2019-05-24 | 2020-12-03 | Integrative Research Laboratories Sweden Ab | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
| CA3180417A1 (en) * | 2020-06-10 | 2021-12-16 | Guillaume Dutheuil | Synthesis of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid |
| WO2025003437A1 (en) | 2023-06-28 | 2025-01-02 | Integrative Research Laboratories Sweden Ab | A pharmaceutical composition comprising a fumaric acid salt of (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0586229A1 (en) * | 1992-09-01 | 1994-03-09 | Zeneca Limited | 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors |
| EP1582524B1 (en) | 2004-04-02 | 2008-08-13 | Ludwig Maximilians Universität | Method of preparing organomagnesium compounds |
| CN101808987A (zh) * | 2007-06-05 | 2010-08-18 | Nsab神经研究瑞典公司分公司 | 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷 |
| WO2010058018A1 (en) * | 2008-11-24 | 2010-05-27 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission |
| CN104447490B (zh) * | 2014-11-19 | 2017-06-06 | 连云港恒运医药有限公司 | 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途 |
-
2018
- 2018-05-18 DK DK18730980.2T patent/DK3625213T3/da active
- 2018-05-18 EP EP18730980.2A patent/EP3625213B1/en active Active
- 2018-05-18 PL PL18730980.2T patent/PL3625213T3/pl unknown
- 2018-05-18 WO PCT/EP2018/063123 patent/WO2018211080A1/en not_active Ceased
- 2018-05-18 ES ES18730980T patent/ES2943252T3/es active Active
- 2018-05-18 CA CA3064136A patent/CA3064136A1/en active Pending
- 2018-05-18 JP JP2019563863A patent/JP7126522B2/ja active Active
- 2018-05-18 FI FIEP18730980.2T patent/FI3625213T3/fi active
- 2018-05-18 US US16/338,055 patent/US11078158B2/en active Active
- 2018-05-18 CN CN201880031878.8A patent/CN110621659B/zh active Active
-
2021
- 2021-06-25 US US17/358,494 patent/US12091384B2/en active Active
-
2024
- 2024-08-13 US US18/802,081 patent/US20240400505A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12091384B2 (en) | 2024-09-17 |
| CA3064136A1 (en) | 2018-11-22 |
| ES2943252T3 (es) | 2023-06-12 |
| US20240400505A1 (en) | 2024-12-05 |
| CN110621659A (zh) | 2019-12-27 |
| JP2020520936A (ja) | 2020-07-16 |
| PL3625213T3 (pl) | 2023-07-17 |
| US20200024231A1 (en) | 2020-01-23 |
| CN110621659B (zh) | 2023-02-28 |
| DK3625213T3 (da) | 2023-04-24 |
| JP7126522B2 (ja) | 2022-08-26 |
| EP3625213A1 (en) | 2020-03-25 |
| EP3625213B1 (en) | 2023-03-08 |
| WO2018211080A1 (en) | 2018-11-22 |
| US11078158B2 (en) | 2021-08-03 |
| US20210317081A1 (en) | 2021-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7299837B2 (ja) | 化合物、組成物、および使用方法 | |
| RU2470011C2 (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| AU2016384921C1 (en) | Crystalline form of BTK kinase inhibitor and preparation method thereof | |
| IL203910A (en) | Therapeutic isoxazole compounds | |
| RU2018130727A (ru) | Органические соединения | |
| FI3625213T3 (fi) | (+)-3-(2,3-Difluorifenyyli)-3-metoksipyrrolidiini-fumaraatti, menetelmä sen valmistamiseksi ja sen käytöt | |
| US10738018B2 (en) | Compounds for therapeutic use | |
| MX2015014353A (es) | Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina. | |
| IL288271B1 (en) | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof | |
| CN110997675A (zh) | 新的取代的黄嘌呤衍生物 | |
| KR20240088949A (ko) | 질병 및 질환의 치료를 위한 lsd 유도체, 합성 및 방법 | |
| WO2022217232A1 (en) | Chromans and benzofurans as 5-ht1a and taar1 agonists | |
| JP2020520936A5 (enExample) | ||
| CN112457305A (zh) | 含三环结构的芳香杂环化合物，及其制备方法和应用 | |
| WO2016067009A1 (en) | Compounds with activity against bacteria and mycobacteria | |
| KR101856046B1 (ko) | 니코틴 수용체 비-경쟁적 길항제 | |
| JP2013504581A (ja) | ヒスタミンｈ３インバースアゴニストおよびアンタゴニストとその使用方法 | |
| CN104955807A (zh) | mGluR3的正变构调节剂 | |
| KR20100017881A (ko) | Ｓ１ｐ 수용체 조절제로서 유용한 벤즈아미드 | |
| KR102471059B1 (ko) | 장애의 치료를 위한 하이드록시노르케타민 유도체 | |
| JP2012509860A5 (enExample) | ||
| AU2018278283B2 (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| CN118715227A (zh) | 大环嘧啶衍生物、其制备方法以及含有其作为活性成分的用于预防或治疗神经退行性疾病的药物组合物 | |
| WO2025157993A1 (en) | Trem2 modulators | |
| CN121001719A (zh) | 羟基烷基色胺和甲氧基烷基色胺 |